Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: French National Agency for Research on AIDS and Viral Hepatitis to ANRS, Emerging Infectious Diseases
    • Study sites: 0 to 1
    • Publications: 2 to 3
    v2
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple combination with protease inhibitor is recommended. Such therapy induces side effects and the number of pills may reduce therapy adherence. The aim of this study is to evaluate the efficacy and the safety of a once daily FTC, ddI, efavirenz combination, in HIV patients with CD4 cell count over 100/mm3, antiretroviral naive.
Trial Details
NCT Number NCT00196599
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Triangle Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, Dupont Applied Biosciences
Conditions
(from sponsor)		 HIV Infections, Antiretroviral Naive
Related terms HIV Infections
Enrollment 39 participants
Start Date
Study Completion (estimated)
Updated on ClinicalTrials.gov